Bosh sahifaMOR • ETR
add
MorphoSys AG
Yopilish kursi
67,65 €
Kunlik diapazon
67,65 € - 68,00 €
Yillik diapazon
14,52 € - 69,75 €
Bozor kapitalizatsiyasi
2,55 mlrd EUR
Oʻrtacha hajm
66,52 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
ETR
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (EUR) | mar, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 27,54 mln | 13,11% |
Joriy xarajat | 289,14 mln | 264,02% |
Sof foyda | -314,96 mln | -608,87% |
Sof foyda marjasi | -1,14 ming | -526,67% |
Har bir ulushga tushum | -8,27 | -529,19% |
EBITDA | -263,38 mln | -388,32% |
Amaldagi soliq stavkasi | 0,51% | — |
Balans
Jami aktivlari
Jami passivlari
| (EUR) | mar, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 630,77 mln | -20,30% |
Jami aktivlari | 1,83 mlrd | -17,85% |
Jami passivlari | 2,09 mlrd | -1,84% |
Umumiy kapital | -261,67 mln | — |
Tarqatilgan aksiyalar | 37,62 mln | — |
Narxi/balansdagi bahosi | -9,72 | — |
Aktivlardan daromad | -34,27% | — |
Kapitaldan daromad | -41,11% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (EUR) | mar, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -314,96 mln | -608,87% |
Operatsiyalardan naqd pul | -71,53 mln | 14,27% |
Sarmoyadan naqd pul | 28,62 mln | 187,62% |
Moliyadan naqd pul | -950,28 ming | 97,86% |
Naqd pulning sof oʻzgarishi | -27,24 mln | 75,37% |
Boʻsh pul | 246,91 mln | 1 523,66% |
Haqida
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Tashkil etilgan
1992
Bosh ofis
Sayt
Xodimlar soni
464
